跳至主要内容
临床试验/NCT02112643
NCT02112643撤回3 期

Selenium - ITEDS: A North American Study

Columbia University0 个研究点开始时间: 2015年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
撤回
主要终点
Change in Thyroid Eye Disease

研究概览

简要总结

The purpose of this study is to determine whether sodium selenite is helpful in the treatment of mild thyroid eye disease in North America.

详细描述

Thyroid eye disease (TED) is a disease in which the soft tissues surrounding the eye can become inflamed, scarred, and at times permanently damaged in an autoimmune reaction highly associated with abnormal thyroid hormone levels. Some patients have much more severe TED than others, but overall, most patients reach a point with relatively stable TED after 1 to 2 years. A recent European study showed that oral selenium, a trace mineral involved in anti-oxidation and immune regulation, could actually alter the course of mild TED, lessening its signs and symptoms and even improving the quality of life of those who took it. The investigators would like to perform a sister study throughout North America. In this randomized, double-blinded, multi-center trial, some subjects with mild TED would be given 100 micrograms of sodium selenite twice a day; others would receive a placebo. Signs, symptoms, and quality of life would be measured at regular intervals throughout the 6 month period of drug administration, and for 6 months thereafter.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 or older
  • Able to provide informed consent
  • Able to swallow pills
  • Mild thyroid eye disease requiring no past treatment other than ophthalmic drops or ointment
  • Euthyroid: at least 2 months if on medication irregardless of thyroidectomy status; at least 6 months after radioiodine therapy; if euthyroid for the year prior to enrollment, needs normal thyroid-stimulating hormone (TSH) within last 3 months; if uncontrolled for the year prior to enrollment, needs normal TSH and free T4 within last 3 months; if TSH low, needs normal T3 and free T4
  • If you are currently taking any selenium supplementation, you will be asked to discontinue its usage, "wash out", for 1 month before you are enrolled.

排除标准

  • Moderate or severe thyroid eye disease (based upon International Thyroid Eye Disease Society VISA form), including: grade 2 chemosis or lid edema; corneal exposure with threat of or resulting in perforation; optic neuropathy; grade 3 restriction of any extraocular muscle
  • Double vision (diplopia) in primary or reading positions
  • Duration of thyroid eye disease greater than 12 months (as per patient history)
  • Drug or alcohol abuse
  • Severe systemic illness (defined by treating physician)
  • Pregnant or breastfeeding

研究组 & 干预措施

Selenium

Active Comparator

100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.

干预措施: Sodium selenate (Drug)

Sugar pill

Placebo Comparator

A placebo pill will be taken orally twice daily for 6 months.

干预措施: Sugar pill (Dietary Supplement)

结局指标

主要结局

Change in Thyroid Eye Disease

时间窗: Twelve months

Difference in Quality of Life score

时间窗: Twelve months

GO-QOL score

次要结局

  • Difference in degrees of restriction(Twelve months)
  • Difference in development of optic neuropathy(Twelve months)
  • Difference in diplopia score(Twelve months)
  • Difference in exophthalmos scores(Twelve months)
  • Difference in eyelid aperture(Twelve months)
  • Difference in Clinical Activity Score(Twelve months)
  • Difference in Quality of Life score(Twelve months)
  • Difference in Inflammatory Index(Twelve months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验